Amarin Corp. (AMRN) Has Soared To A New High On Study Results

Amarin Corp. (AMRN) announced Monday morning that the Vascepa cardiovascular or CV outcomes trial, REDUCE-IT, met its primary endpoint.

from RTT - Hot Stocks https://ift.tt/2MWkpm4
via IFTTT